Journal of Clinical & Experimental Pharmacology

Hidechika Okada

Publications

• Review Article
  HMGB1 Release by C5a Anaphylatoxin is an Effective Target for Sepsis Treatment
  Author(s): Noriko Okada, Masaki Imai, Alan Okada, Fumiko Ono and Hidechika OkadaNoriko Okada, Masaki Imai, Alan Okada, Fumiko Ono and Hidechika Okada
  
  Antibodies to C5a have proven to be effective in treating experimental septic primate models. A 17 amino acid peptide (ASGAPAPGPAGPLRPMF) named PepA binds to C5a and prevents complement-mediated lethal shock in rats. AcPepA harboring an acetyl group at the N-terminal alanine showed increased inhibitory activity against C5a. Cynomolgus monkeys destined to expire from a lethal dose of bacterial endotoxin (4 mg/kg) were rescued by intravenous administration of AcPepA. AcPepA could have interfered with the ability of C5a to stimulate C5L2 which is responsible for HMGB1 release and stimulation of TLR4 as an endogeneous ligand with LPS behavior. The suppression of HMGB1 release by AcPepA administration to LPS-shock monkeys is likely responsible for rescuing the animals. .. View More»
  DOI: 10.4172/2161-1459.1000114

  Abstract PDF